Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

World Journal of Clinical Oncology

Volumn 5, Issue 3, 2014, Pages 529-538

  Crozier, Jennifer A ^a   Swaika, Abhisek ^a   Moreno Aspitia, Alvaro ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adjuvant; Anthracyclines; Breast cancer; Chemotherapy; Neoadjuvant

Indexed keywords

EID: 84929175534     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i3.529     Document Type: Review

References (57)

1. Estimated New Cancer Cases by Sex and Age. Available from: URL: http://www.cancer: acs/groups/content/@ epidemiologysurveilance/documents/document/acspc-037114.pdf
2. Cancer Facts and Figures, 2013. Available from: URL: http://www.cancer: acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf
3. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784-1792 [PMID: 16251534 DOI: 10.1056/NEJMoa050518]
4. Ahmann DL, Bisel HF, Eagan RT, Edmonson JH, Hahn RG. Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. Cancer Chemother Rep 1974; 58: 877-882 [PMID: 4614896]
5. Bonadonna G, Beretta G, Tancini G, De Lena M, Monfardini S, Bajetta E, Fossati Bellani F, Brambilla C, Veronesi U. [Adriamycin in combination and in combined treatment modalities (authors transl)]. Tumori 1974; 60: 393-416 [PMID: 4142149]
6. Buzdar AU, Blumenschein GR, Gutterman JU, Tashima CK, Hortobagyi GN, Smith TL, Campos LT, Wheeler WL, Hersh EM, Freireich EJ, Gehan EA. Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. JAMA 1979; 242: 1509-1513 [PMID: 470088 DOI: 10.1001/jama.242.14.1509]
7. Salmon SE, Wendt A, Jones SE, Jackson R, Giordano G, Miller R, Heusinkveld R, Moon TE. Treatment of early breast cancer with adriamycin-cyclophosphamide with or without radiation therapy: initial results of a brief and effective adjuvant program. Recent Results Cancer Res 1978; 68: 98-104 [PMID: 223207 DOI: 10.1007/978-3-642-81332-0-13]
8. Salmon SE, Jones SE. Studies of the combination of adriamycin and cyclophosphamide (alone or with other agents) for the treatment of breast cancer. Oncology 1979; 36: 40-47 [PMID: 156337 DOI: 10.1159/000225316]
9. Phasing out anthracyclines in breast cancer: Is it time? Available from: URL: http://www.healio.com/hematology-oncology/breast-cancer/news/print/hematologyoncology/{ bccf5629-277b-4591-b4d1-65320a4063e9}/phasing-out-Anthracyclines-in-breast-cancer-is-it-time
10. Breast Cancer Facts and Figures 2011-2012. Available from: URL: http://www.cancer: acs/groups/content/@epidemiologysurveilance/documents/document/acspc-030975.pdf
11. Cheng L, Swartz MD, Zhao H, Kapadia AS, Lai D, Rowan PJ, Buchholz TA, Giordano SH. Hazard of recurrence among women after primary breast cancer treatment-A 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev 2012; 21: 800-809 [PMID: 22426147 DOI: 10.1158/1055-9965.EPI-11-1089]
12. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA. Populationbased validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23: 2716-2725 [PMID: 15837986 DOI: 10.1200/JCO.2005.06.178]
13. Available from: URL: http://www.adjuvantonline.com/index. jsp
14. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826 [PMID: 15591335 DOI: 10.1056/NEJMoa041588]
15. van de Vijver MJ, He YD, vant Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009 [PMID: 12490681 DOI: 10.1056/NEJMoa021967]
16. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167 [PMID: 19204204 DOI: 10.1200/JCO.2008.18.1370]
17. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K. Comparisons between different polychemotherapy regimens for early breast cancer: meta-Analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet 2012; 379: 432-444 [PMID: 22152853 DOI: 10.1016/S0140-6736(11)61625-5]
18. Bonilla L, Ben-Aharon I, Vidal L, Gafter-Gvili A, Leibovici L, Stemmer SM. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-Analysis of randomized controlled trials. J Natl Cancer Inst 2010; 102: 1845-1854 [PMID: 21098761 DOI: 10.1093/jnci/djq409]
19. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with nodepositive breast cancer. JAMA 2006; 295: 1658-1667 [PMID: 16609087 DOI: 10.1001/jama.295.14.1658]
20. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000; 60: 1789-1792 [PMID: 10766158]
21. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM. Apoptosis in human acute myocardial infarction. Circulation 1997; 95: 320-323 [PMID: 9008443 DOI: 10.1161/01.CIR.95.2.320]
22. Harris JR, Ovid Technologies Inc. Diseases of the breast. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2009
23. Curtis RE, Boice JD, Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326: 1745-1751 [PMID: 1594016 DOI: 10.1056/NEJM199206253262605]
24. Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005; 23: 4179-4191 [PMID: 15961765 DOI: 10.1200/JCO.2005.05.029]
25. FDA. PLp: doxorubicin HCl intravenous injection, doxorubicin HCl intravenous injection. New York, 2013
26. FDA. PUCp: ELLENCE(R) intravenous injection, epirubicin HCl intravenous injection. New York, 2013
27. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-2879 [PMID: 12767102 DOI: 10.1002/cncr.11407]
28. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717 [PMID: 496103 DOI: 10.7326/0003-4819-91-5-710]
29. Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, Palmieri C, Plummer CJ, Stanley A, Verrill MW. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 2009; 20: 816-827 [PMID: 19153118 DOI: 10.1093/annonc/mdn728]
30. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13: 699-709 [PMID: 12075737 DOI: 10.1093/annonc/mdf132]
31. Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012; 104: 1293-1305 [PMID: 22949432 DOI: 10.1093/jnci/djs317]
32. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007; 25: 3808-3815 [PMID: 17664460 DOI: 10.1200/JCO.2006.10.4976]
33. Ganz PA, Hussey MA, Moinpour CM, Unger JM, Hutchins LF, Dakhil SR, Giguere JK, Goodwin JW, Martino S, Albain KS. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. J Clin Oncol 2008; 26: 1223-1230 [PMID: 18227530 DOI: 10.1200/JCO.2007.11.8877]
34. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicincyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003; 21: 1195-1204 [PMID: 12663705 DOI: 10.1200/JCO.2003.03.114]
35. Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 4: 1748-1757 [PMID: 3783201]
36. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004; 18: 120-125 [PMID: 14586477 DOI: 10.1038/sj.leu.2403187]
37. Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005; 23: 5166-5170 [PMID: 16051958 DOI: 10.1200/JCO.2005.09.423]
38. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 2651-2658 [PMID: 9704715]
39. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG, Farrar WB. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001; 19: 931-942 [PMID: 11181655]
40. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP. Adjuvant chemotherapy in older women with earlystage breast cancer. N Engl J Med 2009; 360: 2055-2065 [PMID: 19439741 DOI: 10.1056/NEJMoa0810266]
41. Jones S, Holmes FA, OShaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol 2009; 27: 1177-1183 [PMID: 19204201 DOI: 10.1200/JCO.2008.18.4028]
42. Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, ORegan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol 2012; 30: 4071-4076 [PMID: 22826271 DOI: 10.1200/JCO.2011.40.6405]
43. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-1266 [PMID: 7908410 DOI: 10.1056/NEJM199405053301802]
44. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366-3373 [PMID: 21768458 DOI: 10.1200/JCO.2011.35.0868]
45. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-1283 [PMID: 21991949 DOI: 10.1056/NEJMoa0910383]
46. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008; 100: 14-20 [PMID: 18159072 DOI: 10.1093/jnci/djm252]
47. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26: 1231-1238 [PMID: 18250349 DOI: 10.1200/JCO.2007.13.5467]
48. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ. Alteration of topoisomerase II-Alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011; 29: 859-867 [PMID: 21189395 DOI: 10.1200/JCO.2009.27.5644]
49. Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, OMalley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-Analysis of individual patient data. Lancet Oncol 2011; 12: 1134-1142 [PMID: 21917518 DOI: 10.1016/S1470-2045(11)70231-5]
50. Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I, Lindquist DL, Holmes FA, Allison MA, Brooks BD, Portillo RM, Vukelja SJ, Steinberg MS, Stokoe C, Crockett MW, Wang Y, Asmar L, Robert NJ, OShaughnessy J. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-Amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol 2013; 14: 1121-1128 [PMID: 24007746 DOI: 10.1016/S1470-2045(13)70384-X]
51. Tinoco G, Warsch S, Glck S, Avancha K, Montero AJ. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer 2013; 4: 117-132 [PMID: 23386910 DOI: 10.7150/jca.4925]
52. Helwick C. Anthracycline Use Steadily Declining in Early Breast Cancer Population. ASCO Post 2012; 3
53. Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS. Decline in the use of anthracyclines for breast cancer. J Clin Oncol 2012; 30: 2232-2239 [PMID: 22614988 DOI: 10.1200/JCO.2011.40.1273]
54. Roch H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Souli P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Genve J, Asselain B. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24: 5664-5671 [PMID: 17116941 DOI: 10.1200/JCO.2006.07.3916]
55. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol2003; 21: 1431-1439 [PMID: 12668651 DOI: 10.1200/JCO.2003.09.081]
56. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-1671 [PMID: 18420499 DOI: 10.1056/NEJMoa0707056]
57. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-2313 [PMID: 15930421 DOI: 10.1056/NEJMoa043681]